Immune Checkpoint Inhibitor

A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.

The FDA granted orphan drug designation to serplulimab for treatment of small cell lung cancer.

Patients with non-small cell lung cancer and an exceptionally high anti-PD-1 therapy response more frequently had a variant of the CTLA-4 gene, which may be used to identify those who may benefit from such treatment.

Use of an immune checkpoint inhibitor within 90 days of radiation therapy did not increase risk for serious adverse events among patients with cancer, according to a pooled analysis of prospective trial data published in JAMA Oncology.

In this video, Mark W. Ball, MD, discusses the ongoing SWOG S1931 study assessing the use of immune checkpoint inhibitors with or without cytoreductive nephrectomy in patients with renal cell carcinoma.

A blood-based signature of five microRNAs demonstrated the ability to predict OS of patients with lung cancer receiving immunotherapy and stratify them for treatment, according to a study published in npj Precision Oncology.

A randomized phase 3 trial designed to assess the addition of tiragolumab to atezolizumab and chemotherapy for extensive-stage small cell lung cancer failed to meet its co-primary endpoint of PFS.

Atezolizumab administered before and during chemoradiation appeared safe and demonstrated immune-modulating activity among women with node-positive locally advanced cervical cancer, according to study results.

The University of Texas MD Anderson Cancer announced Thursday the launch of the James P. Allison Institute, a research and innovation hub that integrates immunobiology across disciplines to accelerate discoveries toward cancer cures.

Research suggests the gut microbiome plays a role in response to cancer immunotherapy, according to a study published in Nature Medicine.